EdgarLookup

MGT CAPITAL INVESTMENTS, INC. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that MGT CAPITAL INVESTMENTS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-10.8%
Profit Margin
Net income ÷ revenue
-206.6%
Return on Assets
Net income ÷ assets
-1.05x
Debt-to-Equity
Total liabilities ÷ equity
-35.2%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2018 Dec 31, 2018 $2.03M Apr 16, 2019
FY2018 Dec 31, 2017 $3.13M Apr 16, 2019
FY2017 Dec 31, 2016 $313.0K Apr 2, 2018
FY2016 Dec 31, 2015 $104.0K Apr 20, 2017
FY2015 Dec 31, 2014 $94.0K Apr 14, 2016
FY2014 Dec 31, 2013 $396.0K Apr 15, 2015
FY2013 Dec 31, 2012 $409.0K Mar 28, 2014
FY2012 Dec 31, 2011 $536.0K May 31, 2013

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $87.0K Mar 17, 2026
FY2025 Dec 31, 2024 $322.0K Mar 17, 2026
FY2024 Dec 31, 2023 $399.0K Nov 10, 2025
FY2023 Dec 31, 2022 $809.0K Apr 16, 2024
FY2022 Dec 31, 2021 $883.0K Mar 31, 2023
FY2021 Dec 31, 2020 $1.43M Mar 31, 2022
FY2020 Dec 31, 2019 $450.0K Apr 15, 2021
FY2019 Dec 31, 2018 $2.03M Mar 30, 2020

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2017 Dec 31, 2017 $1.63M Apr 2, 2018
FY2017 Dec 31, 2016 $104.0K Apr 2, 2018
FY2016 Dec 31, 2015 $99.0K Apr 20, 2017
FY2015 Dec 31, 2014 $94.0K Apr 14, 2016
FY2014 Dec 31, 2013 ($163.0K) Apr 15, 2015
FY2013 Dec 31, 2012 $144.0K Mar 28, 2014
FY2012 Dec 31, 2011 $432.0K May 31, 2013
FY2011 Dec 31, 2010 $424.0K Mar 1, 2012

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($219.0K) Mar 17, 2026
FY2025 Dec 31, 2024 $5.52M Mar 17, 2026
FY2024 Dec 31, 2023 ($6.13M) Nov 10, 2025
FY2023 Dec 31, 2022 ($5.98M) Apr 16, 2024
FY2022 Dec 31, 2021 ($1.54M) Mar 31, 2023
FY2021 Dec 31, 2020 ($3.89M) Mar 31, 2022
FY2020 Dec 31, 2019 ($8.78M) Apr 15, 2021
FY2019 Dec 31, 2018 ($23.28M) Mar 30, 2020
FY2017 Dec 31, 2017 ($50.43M) Apr 2, 2018
FY2017 Dec 31, 2016 ($24.52M) Apr 2, 2018

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($797.0K) Mar 17, 2026
FY2025 Dec 31, 2024 ($1.12M) Mar 17, 2026
FY2024 Dec 31, 2023 ($1.43M) Nov 10, 2025
FY2023 Dec 31, 2022 ($2.49M) Apr 16, 2024
FY2022 Dec 31, 2021 ($1.79M) Mar 31, 2023
FY2021 Dec 31, 2020 ($2.88M) Mar 31, 2022
FY2020 Dec 31, 2019 ($7.50M) Apr 15, 2021
FY2019 Dec 31, 2018 ($23.92M) Mar 30, 2020
FY2018 Dec 31, 2017 ($21.61M) Apr 16, 2019
FY2017 Dec 31, 2016 ($20.24M) Apr 2, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2019 Dec 31, 2018 $47.0K Mar 30, 2020
FY2018 Dec 31, 2017 $346.0K Apr 16, 2019
FY2017 Dec 31, 2016 $297.0K Apr 2, 2018
FY2015 Dec 31, 2014 $188.0K Apr 14, 2016
FY2014 Dec 31, 2013 $73.0K Apr 15, 2015
FY2013 Dec 31, 2012 $83.0K Mar 28, 2014
FY2012 Dec 31, 2011 $1.14M May 31, 2013
FY2011 Dec 31, 2010 $1.58M Mar 1, 2012

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2014 Dec 31, 2014 $5.51M Apr 15, 2015
FY2014 Dec 31, 2013 $9.12M Apr 15, 2015
FY2013 Dec 31, 2012 $4.55M Mar 28, 2014
FY2012 Dec 31, 2011 $7.15M May 31, 2013
FY2011 Dec 31, 2010 $10.18M Mar 1, 2012

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($991.0K) Mar 17, 2026
FY2025 Dec 31, 2024 ($547.0K) Mar 17, 2026
FY2024 Dec 31, 2023 ($710.0K) Nov 10, 2025
FY2023 Dec 31, 2022 ($2.15M) Apr 16, 2024
FY2022 Dec 31, 2021 ($1.16M) Mar 31, 2023
FY2021 Dec 31, 2020 ($650.0K) Mar 31, 2022
FY2020 Dec 31, 2019 ($3.96M) Apr 15, 2021
FY2019 Dec 31, 2018 ($8.76M) Mar 30, 2020
FY2018 Dec 31, 2017 ($2.38M) Apr 16, 2019
FY2017 Dec 31, 2016 ($5.53M) Apr 2, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 May 13, 2025 $1.35M Mar 17, 2026
FY2023 Dec 31, 2022 $68.0K Apr 16, 2024
FY2022 Dec 31, 2021 $212.0K Mar 31, 2023
FY2021 Dec 31, 2020 $376.0K Mar 31, 2022
FY2020 Dec 31, 2019 $3.65M Apr 15, 2021
FY2019 Dec 31, 2018 $6.99M Mar 30, 2020
FY2018 Dec 31, 2017 $4.07M Apr 16, 2019
FY2017 Dec 31, 2016 $693.0K Apr 2, 2018
FY2016 Dec 31, 2015 $38.0K Apr 20, 2017
FY2014 Dec 31, 2014 $41.0K Apr 15, 2015

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $106.0K Mar 17, 2026
FY2025 Dec 31, 2024 $764.0K Mar 17, 2026
FY2024 Dec 31, 2023 $932.0K Nov 10, 2025
FY2023 Dec 31, 2022 $1.65M Apr 16, 2024
FY2022 Dec 31, 2021 $2.87M Mar 31, 2023
FY2021 Dec 31, 2020 $2.30M Mar 31, 2022
FY2020 Dec 31, 2019 $4.29M Apr 15, 2021
FY2019 Dec 31, 2018 $523.0K Mar 30, 2020
FY2018 Dec 31, 2017 $13.58M Apr 16, 2019
FY2017 Dec 31, 2016 $1.91M Apr 2, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.39M Mar 17, 2026
FY2025 Dec 31, 2024 $3.25M Mar 17, 2026
FY2024 Dec 31, 2023 $9.79M Nov 10, 2025
FY2023 Dec 31, 2022 $5.39M Apr 16, 2024
FY2022 Dec 31, 2021 $1.74M Mar 31, 2023
FY2021 Dec 31, 2020 $1.81M Mar 31, 2022
FY2020 Dec 31, 2019 $1.07M Apr 15, 2021
FY2019 Dec 31, 2018 $1.83M Mar 30, 2020
FY2017 Dec 31, 2017 $1.70M Apr 2, 2018
FY2017 Dec 31, 2016 $2.49M Apr 2, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($2.28M) Mar 17, 2026
FY2025 Dec 31, 2024 ($2.49M) Mar 17, 2026
FY2025 Dec 31, 2023 ($8.86M) Mar 17, 2026
FY2024 Dec 31, 2022 ($3.73M) Nov 10, 2025
FY2023 Dec 31, 2021 $1.13M Apr 16, 2024
FY2022 Dec 31, 2020 $491.0K Mar 31, 2023
FY2021 Dec 31, 2019 $3.23M Mar 31, 2022
FY2020 Dec 31, 2018 ($1.31M) Apr 15, 2021
FY2019 Dec 31, 2017 $11.87M Mar 30, 2020
FY2017 Dec 31, 2016 ($561.0K) Apr 2, 2018

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2016 Dec 31, 2015 $1.50M Apr 20, 2017
FY2015 Dec 31, 2014 $1.50M Apr 14, 2016
FY2015 Dec 31, 2013 $1.50M Apr 14, 2016
FY2014 Dec 31, 2012 $0 Apr 15, 2015

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($426.74M) Mar 17, 2026
FY2025 Dec 31, 2024 ($426.52M) Mar 17, 2026
FY2024 Dec 31, 2023 ($432.04M) Nov 10, 2025
FY2023 Dec 31, 2022 ($425.91M) Apr 16, 2024
FY2022 Dec 31, 2021 ($419.93M) Mar 31, 2023
FY2021 Dec 31, 2020 ($418.39M) Mar 31, 2022
FY2020 Dec 31, 2019 ($414.50M) Apr 15, 2021
FY2019 Dec 31, 2018 ($404.72M) Mar 30, 2020
FY2018 Dec 31, 2017 ($378.90M) Apr 16, 2019
FY2017 Dec 31, 2016 ($328.47M) Apr 2, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $103.0K Mar 17, 2026
FY2025 Dec 31, 2024 $6.0K Mar 17, 2026
FY2024 Dec 31, 2023 $8.0K Nov 10, 2025
FY2023 Dec 31, 2022 $538.0K Apr 16, 2024
FY2022 Dec 31, 2021 $1.23M Mar 31, 2023
FY2021 Dec 31, 2020 $236.0K Mar 31, 2022
FY2020 Dec 31, 2019 $216.0K Apr 15, 2021
FY2019 Dec 31, 2018 $96.0K Mar 30, 2020
FY2018 Dec 31, 2017 $9.52M Apr 16, 2019
FY2018 Dec 31, 2016 $345.0K Apr 16, 2019

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 17, 2026
FY2025 Dec 31, 2024 0 Mar 17, 2026
FY2024 Dec 31, 2023 0 Nov 10, 2025
FY2023 Dec 31, 2022 0 Apr 16, 2024
FY2022 Dec 31, 2021 0 Mar 31, 2023

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 17, 2026
FY2025 Dec 31, 2024 0 Mar 17, 2026
FY2024 Dec 31, 2023 0 Nov 10, 2025
FY2023 Dec 31, 2022 0 Apr 16, 2024

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 4.64B Mar 17, 2026
FY2025 Dec 31, 2024 2.49B Mar 17, 2026
FY2024 Dec 31, 2023 849.17M Nov 10, 2025
FY2023 Dec 31, 2022 703.77M Apr 16, 2024
FY2022 Dec 31, 2021 606.97M Mar 31, 2023
FY2021 Dec 31, 2020 506.78M Mar 31, 2022
FY2020 Dec 31, 2019 413.70M Apr 15, 2021
FY2019 Dec 31, 2018 111.08M Mar 30, 2020
FY2018 Dec 31, 2017 58.96M Apr 16, 2019
FY2017 Dec 31, 2016 28.72M Apr 2, 2018